Arenobufagin induces cell apoptosis by modulating the cell cycle regulator claspin and the JNK pathway in nasopharyngeal carcinoma cells

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71:(3):209–249.
   PubMed Web of Science ®Google Scholar
• Yu H, Yin X, Mao Y, et al. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the global burden of disease study 2019. Eur Arch Otorhinolaryngol. 2022 Mar;279:(3):1519–1533.
   PubMed Web of Science ®Google Scholar
• Taiwan MoHW. Cancer registry annual report 2020. 2022. [ Published 2022 Dec 29; cited 2023 Sep 27]. Available from: https://www.hpa.gov.tw/File/Attach/16434/File_21196.pdf
   Google Scholar
• Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16:(6):645–655.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb;21:(2):342–347.
   PubMed Web of Science ®Google Scholar
• Xue C, Huang Y, Huang PY, et al. Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 2013 Apr;24:(4):1055–1061.
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005 May 20;23(15):3568–3576. doi: 10.1200/JCO.2005.02.147
   PubMed Web of Science ®Google Scholar
• Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev. 1998 Sep;18(5):299–314. doi: 10.1002/(SICI)1098-1128(199809)18:5<299:AID-MED2>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Li M, Wu S, Liu Z, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012 May 1;83(9):1251–1260. doi: 10.1016/j.bcp.2012.01.023
   PubMed Web of Science ®Google Scholar
• Chen L, Mai W, Chen M, et al. Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacol Res. 2017 Sep;123:130–142. doi: 10.1016/j.phrs.2017.07.009
   PubMed Web of Science ®Google Scholar
• Yue Q, Zhen H, Huang M, et al. Proteasome inhibition contributed to the cytotoxicity of Arenobufagin after its binding with Na, K-ATPase in human cervical carcinoma hela cells. PLOS ONE. 2016;11(7):e0159034. doi: 10.1371/journal.pone.0159034
   PubMed Web of Science ®Google Scholar
• Chen K, Li A, Wang J, et al. Arenobufagin causes ferroptosis in human gastric cancer cells by increasing rev-erbα expression. J Tradit Complement Med. 2023 Jan;13:(1):72–80.
   PubMedGoogle Scholar
• Wei X, Yang J, Mao Y, et al. Arenobufagin inhibits the phosphatidylinositol 3-kinase/Protein Kinase B/Mammalian target of rapamycin pathway and induces apoptosis and autophagy in pancreatic cancer Cells. Pancreas. 2020 Feb;49:(2):261–272.
   PubMed Web of Science ®Google Scholar
• Zhang DM, Liu JS, Deng LJ, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013 Jun;34:(6):1331–1342.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yuan B, Bian B, et al. Cytotoxic effects of hellebrigenin and arenobufagin against human breast cancer cells. Front Oncol. 2021;11:711220. doi: 10.3389/fonc.2021.711220
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol. 2020 Jun;38:(6):675–678.
   PubMed Web of Science ®Google Scholar
• Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 2000 Feb;45(3):528–537. doi: 10.1016/S0008-6363(99)00384-3
   PubMed Web of Science ®Google Scholar
• Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012 Nov 1;4(11):a011254–a011254. doi: 10.1101/cshperspect.a011254
   PubMed Web of Science ®Google Scholar
• Ma L, Zhu Y, Fang S, et al. Arenobufagin induces apoptotic cell death in human non-small-cell lung cancer cells via the noxa-related pathway. Molecules. 2017 Sep 11;22(9):1525. doi: 10.3390/molecules22091525
   PubMed Web of Science ®Google Scholar
• Lv J, Lin S, Peng P, et al. Arenobufagin activates p53 to trigger esophageal squamous cell carcinoma cell apoptosis in vitro and in vivo. Onco Targets Ther. 2017;10:1261–1267. doi: 10.2147/OTT.S104767
   PubMed Web of Science ®Google Scholar
• Deng LJ, Peng QL, Wang LH, et al. Arenobufagin intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR pathway. Oncotarget. 2015 Oct 27;6(33):34258–34275. doi: 10.18632/oncotarget.5545
   PubMedGoogle Scholar
• Wang T, Zhuang Z, Zhang P, et al. Effect of arenobufagin on human pancreatic carcinoma cells. Oncol Lett. 2017 Oct;14:(4):4971–4976.
   PubMed Web of Science ®Google Scholar
• Han L, Yuan B, Shimada R, et al. Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87. Int J Oncol. 2018 Dec;53:(6):2488–2502.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009 Jun;9(6):400–414. doi: 10.1038/nrc2657
   PubMed Web of Science ®Google Scholar
• Chini CC, Chen J. Human claspin is required for replication checkpoint control. J Biol Chem. 2003 Aug 8;278(32):30057–30062. doi: 10.1074/jbc.M301136200
   PubMed Web of Science ®Google Scholar
• Semple JI, Smits VA, Fernaud JR, et al. Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell Death Differ. 2007 Aug;14:(8):1433–1442.
   PubMed Web of Science ®Google Scholar
• Tsimaratou K, Kletsas D, Kastrinakis NG, et al. Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol. 2007 Feb;211:(3):331–339.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu WZ, Liu T, et al. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduction Res. 2015;35(6):600–604. doi: 10.3109/10799893.2015.1030412
   PubMed Web of Science ®Google Scholar
• Yue J, Lopez JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020 Mar 28;21(7):2346. doi: 10.3390/ijms21072346
   PubMed Web of Science ®Google Scholar
• Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic bcl-2 family protein BAD. Mol Cell. 2004 Feb 13;13(3):329–340. doi: 10.1016/S1097-2765(04)00028-0
   PubMed Web of Science ®Google Scholar
• Deng LJ, Qi M, Peng QL, et al. Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein. Cancer Cell Int. 2018;18(1):209. doi: 10.1186/s12935-018-0706-9
   PubMedGoogle Scholar
• Han KQ, Huang G, Gu W, et al. Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol. 2007 Jun 28;13(24):3374–3379. doi: 10.3748/wjg.v13.i24.3374
   PubMed Web of Science ®Google Scholar
• Jiaying Y, Bo S, Xiaolu W, et al. Arenobufagin-loaded PEG-PLA nanoparticles for reducing toxicity and enhancing cancer therapy. Drug Deliv. 2023 Dec;30:(1):2177362.
   PubMed Web of Science ®Google Scholar